Biomerica Secures EDA Authorization for Multiple Cancer Screening Tests

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Dec 11 2025

0mins

BMRA+3.96%

Should l Buy BMRA?

Source: Globenewswire

Market Access Breakthrough: Biomerica has received authorization from the Egyptian Drug Authority to promote its rapid screening tests, which is expected to significantly enhance early detection rates for cancers and chronic diseases in Egypt, addressing the growing health needs of the population.
Diverse Product Portfolio: The authorization covers multiple products including the EZ Detect™ Colon Disease Test, Aware® Breast Self Exam, and Fortel Prostate PSA Test, designed to support early disease identification through convenient home testing, thereby reducing healthcare costs.
Addressing Public Health Challenges: With colorectal cancer incidence in Egypt at approximately 5-10 cases per 100,000 people annually, Biomerica's testing tools will aid in identifying high-risk populations, facilitating a shift in national public health policies towards early detection and improving patient outcomes.
Strategic Expansion Plans: This authorization not only strengthens Biomerica's market position in the Middle East and North Africa but also provides opportunities for large-scale screening initiatives in underserved areas, further advancing global preventive healthcare trends.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy BMRA?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on BMRA

About BMRA

Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Biomerica (BMRA) Reports Q2 Loss of $1.32 Million, Revenue Down 26.2%

Jan 15 2026NASDAQ.COM

Widening Losses: Biomerica reported a net loss of $1.32 million in Q2, a 39.5% increase from last year's loss of $0.95 million, indicating greater pressure on the company's profitability.
Revenue Decline: The company's revenue fell to $1.21 million, down 26.2% from $1.64 million last year, reflecting weak market demand and sales challenges that could impact future liquidity.
Performance Comparison: The loss per share widened from $0.09 to $0.12 compared to the same period last year, suggesting that efforts to control costs and boost revenue have not yielded expected results.
Market Outlook: With both revenue and profitability declining, Biomerica may need to reassess its market strategy to navigate the current economic environment and competitive pressures in the industry.

Biomerica (BMRA) Reports Q2 Net Loss of $1.32M, Revenue Down 26.2% YoY

Jan 14 2026seekingalpha

Financial Performance Decline: Biomerica reported a Q2 net loss of $1.32 million, which is a 39% increase from a $0.95 million loss in the same quarter last year, indicating greater pressure on the company's profitability.
Significant Revenue Drop: The company's revenue fell to $1.21 million, down 26.2% year-over-year, reflecting weak market demand and insufficient sales strategies, which could impact future liquidity.
Investor Attention: As financial performance worsens, investor interest in Biomerica is likely to increase, potentially leading to heightened stock price volatility and affecting the company's ability to raise capital in the market.
Uncertain Future Outlook: Given the current financial situation, Biomerica needs to reassess its business strategy to address market challenges and restore growth potential.

Biomerica (BMRA) Launches AI-Driven IBS Test Amid 4% Revenue Decline

Jan 14 2026Globenewswire

Collaborative Promotion: Biomerica entered a marketing services agreement with Henry Schein to support the commercialization of its inFoods®IBS test in the U.S., aiming to enhance awareness among healthcare providers and drive broader adoption in clinical practice.
AI Tool Launch: The introduction of the inFoods®IBS Trigger Food Navigator, an AI-driven digital companion tool designed to improve patient dietary compliance and treatment success, helps patients identify 2 to 4 specific foods that trigger IBS symptoms, providing a personalized dietary plan.
Medicare Payment Rate Established: The CMS set a national Medicare payment rate of $300 for the inFoods®IBS test, effective January 1, 2026, which will expand patient access to the product through the Medicare system, enhancing market penetration.
International Expansion Authorization: The Egyptian Drug Authority authorized Biomerica's complete screening test portfolio, further expanding access to the company's rapid diagnostic solutions in Egypt and supporting the ongoing international expansion of Biomerica's diagnostic products.

Biomerica Announces $300 Medicare Payment for inFoods IBS Test

Dec 23 2025Globenewswire

Medicare Payment Established: CMS has set a national Medicare payment rate of $300 for Biomerica's inFoods IBS test, effective January 1, 2026, which is expected to significantly enhance patient access and lay a foundation for the company's future commercial growth.
Substantial Market Potential: With approximately 30 million IBS patients in the U.S., the inFoods IBS test addresses this unmet medical need through a personalized diagnostic approach, likely driving the company's market share in the rapidly growing gastrointestinal disease sector.
Strong Clinical Validation: In a multicenter randomized controlled trial, 59.6% of patients who eliminated trigger foods identified by the inFoods IBS test achieved abdominal pain reduction, significantly higher than the 42.2% in the control group, providing robust clinical support for product marketing.
Optimized Commercial Strategy: Biomerica plans to use the CMS payment rate as a benchmark for negotiations with private insurers while expanding collaborations with gastroenterology practices to further enhance market penetration.